Cantor Fitzgerald Rates Quince Therapeutics (QNCX) buy

Cantor Fitzgerald maintains its buy rating for Quince Therapeutics, Inc. with a $4.00 price target, a 315.11% upside from the current price.

By TradeTexts Research Desk · Published Jun 23, 2026, 1:02 PM EDT · Updated Jun 26, 2026, 10:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Cantor Fitzgerald rated Quince Therapeutics, Inc. ($QNCX) "buy" with a $4 price target on June 23, 2026.

Since the rating, $QNCX is down 6.0% after 1 week, down 5.6% after 1 month and up 65.4% to date (from the $19.36 close on Jun 23, 2026).

QNCX Quince Therapeutics, Inc.

$32.03 -94.66% year to date

Daily close · Oct 16, 2026

Key Points

Cantor Fitzgerald reiterated its buy rating on Quince Therapeutics, Inc. with a price target of $4.00 on June 23, 2026.
Cantor Fitzgerald's $4 price target implies 315.11% upside from Quince Therapeutics, Inc.'s ($QNCX) current $0.96 share price.
Shares of NasdaqGS:QNCX traded near $0.95 on Tuesday, with a market cap of about $18.1 million.
Recent insider activity at Quince Therapeutics includes significant share purchases by key executives.

Get $QNCX trade alerts by text

We text you when insiders, Congress or big funds trade $QNCX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Quince Therapeutics, Inc. alert may contain errors. Disclosures

Cantor Fitzgerald has reiterated its buy rating for Quince Therapeutics, Inc. (NasdaqGS:QNCX), setting a price target of $4.00. This update came on June 23, 2026, as analyst Olivia Brayer Saunders expressed confidence in the biotechnology company's prospects.

Analyst rating track record

Cantor Fitzgerald vs. the S&P 500

YTD return +16.34% hypothetical

All-time return +36.56% S&P 500 +16.46%

vs. S&P 500 +20.10% ahead of the index

Hypothetical returns from Cantor Fitzgerald's disclosed trades, not real profit or advice. How we model this.

Quince Therapeutics, Inc. Stock Down 96.7%

Shares of Quince Therapeutics traded near $0.95 on Tuesday. The company's market cap stands at approximately $18.1 million. Quince Therapeutics has no meaningful forward P/E ratio due to its lack of profitability, and the stock has a beta of 1.373, indicating moderate volatility. Its 52-week range spans from $0.79 to $45.50, with a 50-day moving average of $1.17 and a 200-day moving average of $13.04. The company maintains a current ratio of 2.917 and a quick ratio of 2.819, with a debt-to-equity ratio of 2.591.

12-month forecast

$QNCX price target

Quince Therapeutics, Inc. daily closes and this analyst's $4 target. Not advice.

Insider Buying and Selling at Quince Therapeutics, Inc.

Recent insider activity at Quince Therapeutics reveals notable transactions. On June 11, 2026, insiders Christopher Senner and David Lamond each purchased 2,700 shares. Brigette Roberts, the Chief Corporate Affairs Officer, acquired over 9.8 million shares on May 18, 2026. Earlier in the year, on January 23, 2026, Brendan Hannah, serving as CBO, COO, and CCO, sold 365,000 shares, while Charles Ryan, the President, bought 200,000 shares.

Analysts Set New Price Targets

On June 23, 2026, Cantor Fitzgerald reiterated its buy rating for Quince Therapeutics with a $4.00 price target. Previously, D. Boral Capital maintained its buy rating with a $5.00 target on January 29, 2026. Analysts generally maintain a positive outlook on the stock, with a consensus buy recommendation and an average target price, reflecting optimism about the company's future.

About Quince Therapeutics

Quince Therapeutics, Inc. is a biotechnology firm based in South San Francisco, California. The company focuses on developing treatments for rare and debilitating diseases. Its lead candidate, eDSP, is in Phase 3 trials for treating a rare pediatric neurodegenerative disease. Quince also utilizes its AIDE technology platform, which combines drug and device technology to encapsulate drugs in a patient's red blood cells. The company was formerly known as Cortexyme, Inc. and rebranded in August 2022.

Bottom Line

Cantor Fitzgerald's reiteration of a buy rating with a $4.00 target highlights confidence in Quince Therapeutics' future potential. Investors track such ratings closely for insights into the company's prospects. As with all 13F filings and analyst ratings, it's important to remember that these are backward-looking and may not reflect current market conditions.